# 2025-19707: Nurse Practitioner Loses Ground in DEA Controlled Substance Battle

2025-19707, Dawn Evert, N.P.; Decision and Order, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2025-10-30, effective 2025-12-01 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-19707
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-19707
- Title: Dawn Evert, N.P.; Decision and Order
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 48888
- Published: 2025-10-30
- Effective: 2025-12-01
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

Nurse Practitioner Loses Ground in DEA Controlled Substance Battle

## Summary

Dawn Evert, a nurse practitioner from Colorado, had her DEA registration suspended and then revoked because she prescribed dangerous drugs without proper medical reasons or monitoring. This decision protects public safety by stopping her from legally prescribing controlled substances. The revocation is final, even though her registration expired in August 2025, so she can’t prescribe these drugs anymore.

## Effects PRIA read

- DEA Registration Revoked for Nurse Practitioner: cost, high. The DEA revoked Dawn Evert's Certificate of Registration No. ME1730870, effective December 1, 2025. Her registration had expired on August 31, 2025, but the Agency nevertheless revoked it and denied any pending applications to renew, modify, or obtain registration in Colorado, so she may no longer…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-19707 on federalregister.gov](https://www.federalregister.gov/documents/2025/10/30/2025-19707/dawn-evert-np-decision-and-order)
- [2025-19707 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-10-30/pdf/2025-19707.pdf)

## Related
- [Previous: 2025-19705, Lawrence Michael Willis, D.D.S.; Decision and Order](https://policyrisk.com/federal-register/2025-19705)
- [Next: 2025-19708, Pharmacy Place, Llc; Decision and Order](https://policyrisk.com/federal-register/2025-19708)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-19707 (as of 2026-06-08).
